HOME CONTROL INTERNATIONAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1747)

VOLUNTARY ANNOUNCEMENT
BUSINESS DEVELOPMENT UPDATE

This announcement is made by Home Control International Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company (the "**Shareholders**") and potential investors with up-to-date information on the Group's strategic layout and planning.

Reference is made to the voluntary announcement of the Company dated 12 September 2025 (the "**Announcement**") in relation to the incorporation of a wholly-owned subsidiary. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the Company has established a wholly-owned limited liability company in Hong Kong, namely Orbiva Limited (the "**Establishment**"). Orbiva Limited is a limited liability company established pursuant to the provisions of the Hong Kong Companies Ordinance and other applicable laws in Hong Kong. The procedures for the Establishment were completed on 22 September 2025.

In view of the growing global demand for healthcare, and the business performance achieved by the Group in the healthcare-related field, the Group, combining its years of technological competence in the fields of IoT and smart remote control with the background of the new directors of the Company, has decided to actively expand into a wider range of healthcare businesses with the newly incorporated Orbiva Limited forming the core of its new strategy.

The Group has started its venture into the healthcare-related business since 2019, focusing on the design, manufacture and sales of products in the hearing-aid accessory category. Such business began to take shape since 2024 and is continuing to grow in 2025. In the Company's Announcement of its Interim Results for the Six Months Ended 30 June 2025 dated 15 August 2025 and its 2025 Interim Report, based on the auditor's opinion, the Company has positioned it under the new business segment of "Healthcare Solutions", which has grown up to approximately 19.7% of the Group's total revenue in the first half of 2025, thanks to increased orders from new customers.

Alongside and concurrent with the existing product-based healthcare-related business that will keep on operating separately under its original structure, the newly incorporated Orbiva Limited and the new brand to be launched will focus on developing the broader healthcare-related businesses, including that of an AIoT-enabled home healthcare platform and ecosystem, and providing healthcare operation services, integrating hardware, software, data and services.

The healthcare business layouts that Orbiva Limited and the new brand will focus on are expected to include the following areas:

– With Home Healthcare as the core, developing an AIoT enabled one-stop health management platform and an ecosystem of products and services:

  Orbiva Limited will self-develop or integrate various intelligent healthcare-related products (such as wearable monitoring devices, intelligent interactive products, integrated control terminals, etc.) in home healthcare and wellness scenarios. It will also build a digital platform based on AIoT and cyber security technologies to link all products in the scenarios and realize the interconnection and interoperability of home healthcare data and further build a "digital health profile" for the residents empowered by AI agent.

– Providing healthcare operation services centered on residents' health management:

  Orbiva Limited will set out to further extend the platform operation capability to link clinics or other primary or community healthcare institutions in order to further integrate residents' healthcare profiles and to build access to a comprehensive healthcare management service system for residents that integrate primary heathcare services, insurance, pharmaceuticals, healthcare products and other healthcare-related services.

In line with the above core healthcare business directions, Orbiva Limited will also cultivate innovative technologies that can be strategically integrated into its development plans, such as AI and Web3 technologies, to enrich the platform's capabilities and expand innovative applications.

The Board takes a positive view on the future development of Orbiva Limited. At the level of technology R&D, Orbiva Limited is exploring cooperation with renowned universities in the form of joint laboratories or other suitable forms; at the supply chain level, it is advancing discussions of product definition and development with several industry-leading hardware suppliers; at the ecosystem level, it has also started preliminary exchanges with Fintech institutions on innovative models. The Board expects progress to be made in terms of relevant cooperation in due course and will continue to explore opportunities with potential partners in line with the aforementioned business directions.

Shareholders and potential investors should note that this announcement is made on a voluntary basis for the purpose of keeping the public informed of the latest business development of the Company. There is no assurance that the plans or developments mentioned in this announcement will be successfully implemented. Further announcement(s) will be made by the Company in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as and when appropriate or required. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Home Control International Limited
Kwok Hoong SIU
Chief Executive Officer and Executive Director

Hong Kong, 25 September 2025

As of the date of this announcement, the Board comprises Mr. Kwok Hoong SIU and Mr. Haofang YANG as executive Directors; Mr. Alain PERROT and Ms. Ying MA as non-executive Directors; and Mr. Werner Peter VAN ECK, Dr. Shou Kang CHEN, Ms. Keet Yee LAI, Mr. Min YE and Mr. Yi Chung CHEN as independent non-executive Directors.